Featured Studies Results
Keyword: BRCA1
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)
https://www.facingourrisk.org/research-clinical-trials/study/425 /a-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-or-darolutamide-talent
Clinicaltrials.gov identifier:
NCT06844383 (https://clinicaltrials.gov/show/NCT06844383)
Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation
Research Study on the Genetics of Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/317 /research-study-on-the-genetics-of-breast-cancer
Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266 /helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Clinicaltrials.gov identifier:
NCT07318363 (https://clinicaltrials.gov/show/NCT07318363)
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations
https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations
Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers
Family Study for People with Certain Rare BRCA1 or BRCA2 Variants
https://www.facingourrisk.org/research-clinical-trials/study/428 /family-study-for-people-with-certain-rare-brca1-or-brca2-variants
Surveys, Registries, Interviews
Family study for adults with a known rare BRCA1 or BRCA2 variant in themselves or a relative
Testing a New Targeted Therapy ETX-19477 to Treat Advanced Breast, Colorectal Endometrial, Ovarian or Pancreatic Cancer in People with a BRCA2 Mutation (ERADIC8)
https://www.facingourrisk.org/research-clinical-trials/study/432 /testing-a-new-targeted-therapy-etx-19477-to-treat-advanced-solid-tumors-eradic8
Clinicaltrials.gov identifier:
NCT06395519 (https://clinicaltrials.gov/show/NCT06395519)
Treatment
Phase 1/2 treatment study for people with advanced breast, colorectal, endometrial, ovarian or pancreatic cancer
Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/392 /evaluating-the-safety-of-nipple-sparing-mastectomy-in-women-with-a-high-risk-for-breast-cancer
Clinicaltrials.gov identifier:
NCT06888388 (https://clinicaltrials.gov/show/NCT06888388)
Prevention
Study for people considering double mastectomy to reduce breast cancer risk
Vaccine for People at High Risk for Pancreatic Cancer
https://www.facingourrisk.org/research-clinical-trials/study/365 /vaccine-for-those-at-high-risk-of-developing-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05013216 (https://clinicaltrials.gov/show/NCT05013216)
Prevention
Phase 1 pancreatic cancer prevention study for people at high risk
A Study of Fallopian Tube Removal with Delayed Ovary Removal to Lower Ovarian Cancer Risk (TUBA-WISP-II)
https://www.facingourrisk.org/research-clinical-trials/study/404 /
Clinicaltrials.gov identifier:
NCT04294927 (https://clinicaltrials.gov/show/NCT04294927)
Prevention
Prevention study for women at high risk for ovarian cancer
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/353 /using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)
Prevention
Screening for people at high risk for prostate cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300 /study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD
https://www.facingourrisk.org/research-clinical-trials/study/361 /testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
A Study of the PARP Inhibitor Saruparib Added to Standard Treatment for High Risk BRCA-Positive Prostate Cancer (EvoPAR PR02)
https://www.facingourrisk.org/research-clinical-trials/study/369 /a-study-of-the-parp-inhibitor-saruparib-added-to-standard-treatment-for-high-risk-brca1-positive-prostate-cancer
Clinicaltrials.gov identifier:
NCT06952803 (https://clinicaltrials.gov/show/NCT06952803)
Treatment
Phase 3 treatment study for BRCA-positive high-risk prostate cancer
A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation
https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations
Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)
Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer
Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)
https://www.facingourrisk.org/research-clinical-trials/study/349 /studying-a-new-parp-inhibitor-and-hormonal-therapy-to-treat-her2-negative-hr-positive-metastatic-breast-cancer-with-a-brca1-brca2-or-palb2-mutation-evopar-br01
Clinicaltrials.gov identifier:
NCT06380751 (https://clinicaltrials.gov/show/NCT06380751)
Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib
Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)
Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation
Pancreatic Cancer Screening Study (CAPS5)
https://www.facingourrisk.org/research-clinical-trials/study/222 /pancreatic-cancer-screening-studycaps5
Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)
Prevention
Screening study for people at high risk for pancreatic cancer
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.